@article {7413,
	title = {When to recommend a second autograft in patients with relapsed myeloma?},
	journal = {Leukemia and Lymphoma},
	volume = {58},
	year = {2017},
	note = {Export Date: 21 February 2017},
	month = {2017},
	pages = {781 - 787},
	abstract = {In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {multiple myeloma, relapse, Second ASCT},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84999810220\&doi=10.1080\%2f10428194.2016.1246729\&partnerID=40\&md5=4d4675f6b9428398c6e5fdafa5dc0c3c},
	author = {Ziogas, D.C. and Terpos, E. and Dimopoulos, M.A.}
}
